Innovation lies at the heart of interventional cardiology and cardiovascular surgery. Both fields have advanced because of professionals willing to challenge apparently insurmountable technical boundaries and to find solutions for patients who, in earlier times, would simply have had no therapeutic options. Unfortunately, in this regard, the study “Transcatheter aortic valve-in-mechanical valve replacement: a first-in-human study” represents a milestone that is more open to criticism than to praise.
The authors describe the first successful experience of transcatheter valve implantation inside mechanical prostheses. Specifically, the study reports a preclinical experience in pigs and 3 patient cases. However, none of these cases provides clinical data supporting an extraordinarily complex clinical scenario that would have justified refusal of surgery because the risk was deemed prohibitive. This point should be emphasized from the outset: although the sound judgement of the clinicians responsible for these patients cannot be questioned, the study does not provide enough information to reasonably justify the proposed alternative over conventional surgery—whether the patient was rejected at the referring centre, whether the decision was made by a Heart Team, whether referral to another centre with better outcomes or greater expertise was considered, or whether second opinions from nationally recognized surgeons were sought.
Several further criticisms should be added to this initial consideration. Beyond the clinical success of the procedures, it is particularly striking that experience gained from 9 porcine animal models was considered sufficient to undertake an approach that falls outside any clinical recommendation. Indeed, the study attempts to mask the absence of real uncertainty regarding improvisation by stating that the procedure was preceded by a careful phase of preclinical testing, including animal models and dedicated simulations aimed at understanding technical feasibility, the interaction between the mechanical prosthesis and the transcatheter valve, and the potential risks of the procedure, such as the need to capture—and the consequences of failing to capture—the embolized prosthetic material. At a time when innovation sometimes seems to move faster than reflection, this study illustrates the risk of prioritizing technical feasibility and the impact of early reporting over a more measured clinical assessment of indication, proportionality, and procedural safety. Experience in 9 porcine cases does not seem sufficient to perform a procedure for the first time in any human being.
On the other hand, the recent history of structural intervention obliges us to look beyond isolated cases. The debate raised by this article is not about the patients who were treated. We are not going to question whether they were exactly the type of patients in whom such a strategy should have been attempted. The debate concerns what happens after publications of this kind.
Experience has shown us that the indications for many technologies rarely remain where they began. TAVI is probably the clearest example. Initially reserved for inoperable patients or those at prohibitive surgical risk, it subsequently moved into high-risk, then intermediate-risk, and finally low-risk populations. Each step was supported by a growing body of evidence pointing in the same direction, although with progressively less stringent design and interpretation. However, it was also accompanied by a phenomenon that is difficult to ignore: once enough experience with a technology has been gained, the temptation to explore new frontiers becomes almost inevitable. Thus, today we find ourselves discussing TAVI in asymptomatic patients, in patients with moderate stenosis and ventricular dysfunction, in bicuspid valves, and in increasingly younger populations. Some of these indications may ultimately prove useful. Others may not. What is unacceptable is to consider them valid merely because they are feasible, to take them for granted on the basis of insufficient evidence, and, above all, to assume they are superior when an established treatment alternative exists, developed through years of experience, research, and follow-up.
Therefore, the question is not whether these patients should have undergone valve-in-mechanical valve implantation. The question is whether, in ten years’ time, we will still regard this strategy as an extraordinary solution for extraordinary patients, or whether accumulated experience will progressively displace principles such as the need for controlled management of embolized material as a fundamental prerequisite for considering the procedure. Seen in this light, it is hard not to recall Groucho Marx: “These are my principles. If you don’t like them, I have others.” The same may apply to indications and to the sound principles of surgical or interventional practice.
COMMENTARY:
Studies such as this should be interpreted with balance. They deserve cautious admiration for the courage (especially that of the patients who consent to these procedures) required to open new therapeutic alternatives. However, they also demand critical reflection on their place within the evidence base and their true clinical relevance.
Innovation transforms medicine when it offers solutions where none previously existed. The risk emerges when the success of those solutions makes us forget why they were conceived in the first place. The distance between heroism/innovation and negligence may be a very thin line. May this commentary serve as a call for prudence, even if, like the fragments of mechanical prosthetic valve leaflets, we no longer know where such prudence can be found today.
REFERENCE:
Amat-Santos IJ, Real C, Galán-Arriola C, Diz-Díaz J, Párraga R, Pérez-Camargo D, et al. Transcatheter aortic valve-in-mechanical valve replacement: a first-in-human study. Eur Heart J. 2026 May 5;47(17):2107-2109. doi: 10.1093/eurheartj/ehag019. PMID: 41614684.
